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The paper by Delamain et al., published in this issue of the Revista Brasileira de Hematologia e Hemoterapia (RBHH), addresses the main findings of DLBCGL in a multicenter retrospective study with 104 patients from three countries, Brazil, Portugal and Italy. This kind of study is very important in rare diseases since the majority of the recommendations are based on data from case series, rather than large randomized trials. 10 Different to the literature, the authors found a slightly higher incidence in women, advanced stage and high-risk age-adjusted international prognostic index (aaIPI) at diagnosis. The median age was in agreement with the current literature and 13% of the patients were positive for H. pylori. Few patients required surgery because of complications. The patients were treated with rituximab with the cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate and prednisone regimen (R-CHOP) with or without radiotherapy and the authors got impressive results considering not only complete remission, but also overall survival rates. They also contribute to the literature by identifying the aaIPI as a predictor factor for the survival of patients. 
Conflicts of interest
The author declares no conflicts of interest. r e f e r e n c e s
